Page last updated: 2024-12-08
7-deoxyloganic acid
Description
7-deoxyloganic acid: from Uncaria tomentosa; a cyclopentyl pyran [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
7-deoxyloganic acid : A cyclopentapyran that is 1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acid substituted at positions 1 and 7 by beta-D-glucosyloxy and methyl groups respectively (the 1S,4aS,7S,7aR-diatereomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 443322 |
CHEBI ID | 2260 |
SCHEMBL ID | 20572414 |
MeSH ID | M0395800 |
Synonyms (12)
Synonym |
7-deoxyloganic acid |
CHEBI:2260 |
bis-desoxydihydromonotropein |
(1s,4as,7s,7ar)-1-(beta-d-glucopyranosyloxy)-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acid |
SCHEMBL20572414 |
DTXSID40945163 |
Q19596786 |
cyclopenta(c)pyran-4-carboxylic acid, 1-(.beta.-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-7-methyl-, (1s-(1.alpha.,4a.alpha.,7.alpha.,7a.alpha.))- |
(1s,4as,7s,7ar)-1-(beta-d-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-7-methylcyclopenta[c]pyran-4-carboxylic acid |
bisdeoxydihydromonotropein |
cyclopenta(c)pyran-4-carboxylic acid, 1.alpha.-(.beta.-d-glucopyranosyloxy)-1,4a.alpha.,5,6,7,7a.alpha.-hexahydro-7.alpha.-methyl- |
AKOS040735291 |
Roles (1)
Role | Description |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (6)
Class | Description |
beta-D-glucoside | Any D-glucoside in which the anomeric centre has beta-configuration. |
cyclopentapyran | |
monoterpene glycoside | A terpene glycoside in which the terpene moiety is a monoterpenoid. |
monosaccharide derivative | A carbohydrate derivative that is formally obtained from a monosaccharide. |
iridoid monoterpenoid | One of a class of monoterpenoids biosynthesized from isoprene and often intermediates in the biosynthesis of alkaloids. Iridoids usually consist of a cyclopentane ring fused to a six-membered oxygen heterocycle; cleavage of a bond in the cyclopentane ring gives rise to the subclass known as secoiridoids. |
alpha,beta-unsaturated monocarboxylic acid | A monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.42 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 4.72 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |